New trends in the treatment of diabetic nephropathy in children

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 8, 2002, Pages 1169-1176

  Verrotti, Alberto ^a   Trotta, Daniela ^a   di Corcia, Giovanna ^a   Chiarelli, Francesco ^a  

^a Policlinico   (Italy)

Author keywords

Childhood; Diabetes; Hypertension; Microalbuminuria; Treatment

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; IRBESARTAN; LOSARTAN; NITRENDIPINE; PERINDOPRIL; PROSTAGLANDIN; RAMIPRIL; VERAPAMIL; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; CHILD; CONTROLLED STUDY; COUGHING; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DRUG ELIMINATION; DRUG HALF LIFE; FATIGUE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MICROALBUMINURIA; NEUTROPENIA; PROTEINURIA; REVIEW; RISK ASSESSMENT; RISK FACTOR; VERTIGO; CLASSIFICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; RANDOMIZED CONTROLLED TRIAL;

ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CHILD; DIABETES MELLITUS, INSULIN-DEPENDENT; DIABETIC NEPHROPATHIES; HUMAN; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ANGIOTENSIN; DIABETES MELLITUS, TYPE 1; HUMANS;

EID: 0035989250     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.8.1169     Document Type: Review

References (65)

1. Controversies on the prevention of diabetic nephropathy
2. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
3. Declining incidence of nephropathy in insulin-dependent diabetes mellitus
4. Current strategies for retarding progression of renal disease
5. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with Type 2 diabetes
6. Remission and regression in the nephropathy of Type 1 diabetes when blood pressure is controlled aggressively
7. Definition of diabetic renal disease in insulin-dependent diabetes mellitus based on renal function tests
8. Pathogenesis, prevention and treatment of diabetic nephropathy
9. Diabetic nephropathy in childhood and adolescents
10. Preserving renal function in adults with hypertension and diabetes: A consensus approach
11. Enlargement of the juxtaglomerular apparatus in insulin-dependent diabetes mellitus patients with microalbuminuria
12. Ambulatory blood pressure in the transition from normo- to microalbuminuria: A longitudinal study in IDDM patients
13. Size- and charge-selectivity of glomerular filtration in IDDM patients with and without albuminuria
14. Appropriate blood pressure control in diabetes. Part 2 with valsartan
15. Follow-up study of glomerular dimensions and cortical interstitium in microalbuminuric Type 1 diabetic patients with or without antihypertensive treatment
16. Hypertension in patients with diabetes. Overcoming barriers to effective control
17. Prevalence and management of hypertension in Type 1 diabetes mellitus in Europe: The EURODIAB IDDM Complications Study
18. Blood pressure does not rise before the onset of microalbuminuria in children followed from diagnosis of Type 1 diabetes
19. Renal arterioles in patients with Type I diabetes and microalbuminuria before and after treatment with antihypertensive drugs
20. The juxtaglomerular apparatus in young type-1 diabetic patients with microalbuminuria. Effect of antihypertensive treatment
21. Effect of antihypertensive treatment on kidney function in diabetic nephropathy
22. Long-term anti-hypertensive treatment inhibiting progression of diabetic nephropathy
23. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension
24. Effect of lisinopril on progression of retinopathy in normotensive people with Type 1 diabetes
25. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria
26. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria
27. Effect of angiotensin converting enzyme inhibitor or beta blocker on glomerular structural changes in young microalbuminuric patients with Type I (insulin-dependent) diabetes mellitus
28. Randomised controlled trial of dual blockade of reninangiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study
29. Workshop: Endothelial cell dysfunction leading to diabetic nephropathy: Focus on nitric oxide
30. Increased circulating nitric oxide in young patients with Type 1 diabetes and persistent microalbuminuria: Relation to glomerular hyperfiltration
31. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
32. Low-dose ramipril reduces microalbuminuria in Type 1 diabetic patients without hypertension: Results of a randomized controlled trial
33. Should all patients with Type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data
34. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function
35. Renal considerations in angiotensin converting enzyme inhibitor therapy: A statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High blood pressure American Heart Association
36. Effects of antihypertensive treatment on vascular remodeling in essential hypertensive patients
37. Diabetic nephropathy in children and adolescents: A critical review with particular reference to angiotensin-converting enzyme inhibitors
38. Effect of angiotensin inhibitors on renal injury and angiotensin receptor expression in early hypertensive nephrosclerosis
39. Optimizing antihypertensive therapy in patients with diabetic nephropathy
40. Angiotensin converting enzyme inhibitor therapy to decrease microalbuminuria in normotensive children with insulin dependent diabetes mellitus
41. Angiotensin converting enzyme inhibition in normotensive diabetic adolescents with persistent micro-albuminuria
42. Enalapril reduces microalbuminuria in young normotensive patients irrespective of its hypotensive effect
43. Effects of the ACE inhibitor, enalapril, in children age 6-16 years with hypertension
44. Multicenter study of enalapril pharmacokinetics in hypertensive children and infants
45. Efficacy and safety of captopril in the treatment of severe childhood hypertension: Report of the International Collaborative Study Group
46. Detection and management of diabetic glomerulopathy in children and adolescents with insulin-dependent diabetes mellitus: Need for improved knowledge and better care
47. Antihypertensive effect and pharmacokinetics of nitrendipine in children
48. Efficacy of amlodipine in pediatric patients with hypertension
49. A crossover comparison of extended release felodipine with prolonged action nifedipine in hypertension
50. Effect of enalapril and nitrendipine on exercise albuminuria in normotensive Type I diabetic patients with incipient nephropathy
51. Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes
52. Nitrendipine and enalapril in the treatment of diabetic hypertensive patients with microalbuminuria
53. Effect of 1-year treatment with nitrendipine versus enalapril on urinary albumin and alpha 1-microglobulin excretion in microalbuminuric patients with Type 1 diabetes mellitus. A randomized, single-blind comparative study
54. Nephroprotective effects of nitrendipine in hypertensive Type I and Type II diabetic patients
55. A double-blind trial of perindopril and nitrendipine in incipient diabetic nephropathy
56. Angiotensin II generation at the cell surface of activated neutrophils: Novel cathepsin G-mediated catalytic activity that is resistant to inhibition
57. Angiotensin II subtype 1 receptor blockers and renal function
58. Angiotensin II receptor antagonists
59. Angiotensin-II receptor antagonists: Their place in therapy
60. The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure
61. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes
62. The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes
63. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy
64. Renoprotective effects of angiotensin II receptor blockade in Type 1 diabetic patients with diabetic nephropathy
65. Microalbuminuria prevalence varies with age, sex and puberty in children with Type 1 diabetes followed from diagnosis in a longitudinal study